Q&A with Gary Waanders Healthcare Research Director at Zeus Capital

Zeus Capital Healthcare Research Director Gary Waanders caught up with DirectorsTalk to discuss Quantum Pharma PLC (LON:QP)

 

Q1: Now Quantum Pharma today reported its interim results and warned on profit expectations, what’s happened to performance?

A1: Overall the company has continued to perform relatively well particularly the core Specials business which is generating roughly around £10 million of the EBITDA on an annual basis but there have been a couple of issues that have resulted in challenges to group profitability. The first of these was the acquisition of a company called Nupharm, back in July 2015, which was to be integrated into the Specials division of Quantum, this company was bought whilst in special measures which effectively limited the range of products it could manufacturer under regulation from the MHRA. Now regrettably since the acquisition Quantum has uncovered further operational issues at Nupharm resulting in ongoing losses despite having invested time and money in the company since it was acquired. The second issue is the challenge to sales growth in the niche pharmaceutical division which has been caused by high levels of competition in generic plus products and medical devices, the sales of this category product have not met the company’s own expectations which, with hindsight, we think we’re probably set unrealistically high.

 

Q2: So what corrective measures has the company taken?

A2: So the Board is at a position where it considers that the issues at Nupharm cannot be remedied even with further investment and it has therefore resolved to exit the business as it was continuing to make unacceptable losses, it has therefore begun consultation with a view to closure of the business by the end of December this year. On the niche pharmaceutical side, the generic and generic plus products and medical devices are now going to be deprioritised in favour of the core strategy of that group of obtaining licences for the unlicensed Specials that Quantum Pharma is well known for and this is the so-called unlicensed to licenced product development programme where the company has had some recent quite positive experience.

 

Q3: So with all this in mind, has your view on Quantum Pharma changed?

A3: We’ve downgraded our profit forecasts for the current year and the coming year so now we expect adjusted EBITDA of £10 million in the current year, to January 31st 2017 that is, and £11.5 million and £13 million in the subsequent 2 years. Now we remain confident that the company can hit these targets based on the revised strategy of focussing on its key operational strengths in the Specials division without Nupharm and the niche pharmaceutical division with more unlicensed to licenced emphasis. So the current share price of around 37p and on the basis of our lower profit forecast the company is very attractively valued at just a little over about 7 times EBITDA multiple which is a significant discount to other companies in its peer group.

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    Twitter
    LinkedIn
    Quantum Pharma

    More articles like this

    Quantum Pharma Plc

    Quantum Pharma Plc FY17 Results – A Year of Change

    Quantum Pharma plc (LON:QP), the service-led niche pharmaceutical developer and supplier to the health and care sectors, has reported its Preliminary financial results for the 12 months to January 31, 2017. Net sales grew by 28%

    Quantum Pharma Plc

    Quantum Pharma PLC makes strategic financial appointment

    County Durham based Quantum Pharma has bolstered its executive team with the help of business advisers UNW. The niche pharmaceutical developer and manufacturer, which supplies a range of innovative products to wholesalers, retailers and hospitals, approached

    Quantum Pharma Plc

    Quantum Pharma reduces debt after taking strategic action

    Niche pharma firm Quantum Pharma says it is on target to meet market expectations after taking action to tighten its focus. The Burnopfield pharmaceutical developer , manufacturer and supplier issued a trading update for the year

    Quantum Pharma Plc

    Quantum Pharma PLC Pre-close trading update – on plan

    Quantum Pharma plc (LON:QP), the service-led niche pharmaceutical manufacturer, developer and supplier to the health and care sectors, has released a pre-close trading update this morning. Zeus Capital said: The Board has indicated that adjusted EBITDA

    Quantum Pharma Plc

    Quantum Pharma Plc CFO purchases shares in the PLC

    Quantum Pharma Plc (AIM: QP.), the service-led niche pharmaceutical developer, manufacturer and supplier to the health and care sectors, announces that on 3 January 2017 the Company was notified that Gerard Murray, Quantum’s Chief Financial Officer

    DirectorsTalk

    Quantum Pharma Plc “A good first half year”

    Quantum Pharma Plc (AIM: QP.), the growing, service-led niche pharmaceutical manufacturer, developer and supplier to the health and care sectors, has today given DirectorsTalk its half year results for the six months to 31 July 2015,